ArticleResearch and practice in thrombosis and haemostasis2026
Mortality and complications in low-dose vs standard-dose unfractionated heparin anticoagulation for extracorporeal membrane oxygenation: a systematic review and meta-analysis.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Controversies exist in anticoagulation practices in extracorporeal membrane oxygenation (ECMO). It is uncertain whether the intensity of anticoagulation affects ECMO outcomes. Objectives: To conduct a meta-analysis to determine whether anticoagulation intensity affects ECMO outcomes. Methods: The Medical Literature Analysis and Retrieval System Online, Embase, and Central Register of Controlled Trials' databases were searched from inception to October 2024 for trials comparing the use of low-dose (LD) and standard-dose unfractionated heparin anticoagulation in patients on ECMO. The primary outcome was short-term mortality. Secondary outcomes included major bleeding events, intracranial hemorrhage (ICH), oxygenator changes, systemic thrombotic events, and ECMO duration. Data were pooled using a random-effects meta-analysis. The risk-of-bias was assessed using the Cochrane Risk-of-Bias 2 tool for randomized controlled trials and the Risk-of-Bias in Non-Randomized Studies of Interventions for nonrandomized controlled trials. Results: Seven studies with 619 patients were included. LD anticoagulation was associated with significant reduction in the relative risk (RR) of mortality compared to standard-dose anticoagulation (RR, 0.69; 95% CI, 0.52-0.91; Conclusion: This meta-analysis suggests that LD unfractionated heparin anticoagulation is associated with significantly better survival and a lower risk of ICH without an increase in the risk of thrombotic events. LD anticoagulation should be considered a reasonable strategy in ECMO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.